Celldex Therapeutics, Inc. (CLDX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
53 FRONTAGE ROAD HAMPTON, NJ 08827 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 755,999 | 802,317 | 823,846 | 423,598 | 235,348 | 252,697 | |||
| Cash and cash equivalent | 36,399 | 42,739 | 115,077 | 34,814 | 21,134 | 28,224 | |||
| Short-term investments | 719,600 | 759,578 | 708,769 | 388,784 | 214,214 | 224,473 | |||
| Other undisclosed current assets | 22,843 | 9,658 | 11,478 | 8,095 | 10,585 | 12,123 | |||
| Total current assets: | 778,842 | 811,975 | 835,324 | 431,693 | 245,933 | 264,820 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 3,170 | 2,450 | 2,165 | 2,577 | 2,864 | 3,256 | |||
| Property, plant and equipment | 4,230 | 3,864 | 4,061 | 4,060 | 4,162 | 3,938 | |||
| Intangible assets, net (including goodwill) | 27,190 | 27,190 | 27,190 | 27,190 | 27,190 | 27,190 | |||
| Intangible assets, net (excluding goodwill) | 27,190 | 27,190 | 27,190 | 27,190 | 27,190 | 27,190 | |||
| Prepaid expense | 9,600 | ||||||||
| Other noncurrent assets | 9,747 | 107 | 107 | 107 | 107 | 107 | |||
| Other undisclosed noncurrent assets | (9,600) | ||||||||
| Total noncurrent assets: | 44,337 | 33,611 | 33,523 | 33,934 | 34,323 | 34,491 | |||
| TOTAL ASSETS: | 823,179 | 845,586 | 868,847 | 465,627 | 280,256 | 299,311 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 29,318 | 22,396 | 20,770 | 25,523 | 22,057 | 13,138 | |||
| Accounts payable | 1,114 | 3,802 | 3,234 | 3,494 | 3,586 | 881 | |||
| Accrued liabilities | 28,204 | 18,594 | 17,536 | 22,029 | 18,471 | 12,257 | |||
| Other liabilities | 1,396 | 3,673 | 3,877 | 3,988 | 4,232 | 978 | |||
| Other undisclosed current liabilities | 1,379 | 1,589 | 1,644 | 1,614 | 1,547 | 1,530 | |||
| Total current liabilities: | 32,093 | 27,658 | 26,291 | 31,125 | 27,836 | 15,646 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 5,181 | 4,269 | 3,943 | 5,331 | 5,702 | 6,128 | |||
| Other liabilities | 3,473 | 3,473 | 3,473 | 4,403 | 4,403 | 4,403 | |||
| Operating lease, liability | 1,708 | 796 | 470 | 928 | 1,299 | 1,725 | |||
| Total noncurrent liabilities: | 5,181 | 4,269 | 3,943 | 5,331 | 5,702 | 6,128 | |||
| Total liabilities: | 37,274 | 31,927 | 30,234 | 36,456 | 33,538 | 21,774 | |||
| Equity | |||||||||
| Equity, attributable to parent | 785,905 | 813,659 | 838,613 | 429,171 | 246,718 | 277,537 | |||
| Common stock | 66 | 66 | 66 | 56 | 47 | 47 | |||
| Additional paid in capital | 2,288,683 | 2,277,824 | 2,266,472 | 1,823,168 | 1,598,591 | 1,591,213 | |||
| Accumulated other comprehensive income | 5,288 | 1,780 | 2,244 | 3,308 | 2,135 | 2,072 | |||
| Accumulated deficit | (1,508,132) | (1,466,011) | (1,430,169) | (1,397,361) | (1,354,055) | (1,315,795) | |||
| Total equity: | 785,905 | 813,659 | 838,613 | 429,171 | 246,718 | 277,537 | |||
| TOTAL LIABILITIES AND EQUITY: | 823,179 | 845,586 | 868,847 | 465,627 | 280,256 | 299,311 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 3,191 | 2,498 | 156 | 4,131 | 1,517 | 268 | ||
| Cost of revenue | ||||||||
| Other undisclosed gross profit | (300) | |||||||
| Gross profit: | 3,191 | 2,498 | 156 | 3,831 | 1,517 | 268 | ||
| Operating expenses | (55,317) | (48,815) | (40,764) | (51,758) | (42,756) | (33,473) | ||
| Other undisclosed operating income | 300 | |||||||
| Operating loss: | (52,126) | (46,317) | (40,608) | (47,627) | (41,239) | (33,205) | ||
| Loss from continuing operations before equity method investments, income taxes: | (52,126) | (46,317) | (40,608) | (47,627) | (41,239) | (33,205) | ||
| Other undisclosed income from continuing operations before income taxes | 13,113 | |||||||
| Net loss attributable to parent: | (52,126) | (46,317) | (40,608) | (34,514) | (41,239) | (33,205) | ||
| Other undisclosed net income (loss) available to common stockholders, basic | 10,005 | 10,475 | 7,800 | (8,792) | 2,979 | 2,703 | ||
| Net loss available to common stockholders, diluted: | (42,121) | (35,842) | (32,808) | (43,306) | (38,260) | (30,502) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (52,126) | (46,317) | (40,608) | (34,514) | (41,239) | (33,205) | ||
| Comprehensive loss: | (52,126) | (46,317) | (40,608) | (34,514) | (41,239) | (33,205) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 13,513 | 10,011 | 6,736 | (7,619) | 3,042 | 2,652 | ||
| Comprehensive loss, net of tax, attributable to parent: | (38,613) | (36,306) | (33,872) | (42,133) | (38,197) | (30,553) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.